Doha

Futó vizsgálatok

• Toboroz

  CHARM Hepatocellular Carcinoma MEA Study

  NCT07650773· Forrás

• Toboroz

  BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy

  NCT07597993· Forrás

• Toboroz

  A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region

  NCT07065344· Forrás

• Toboroz

  INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use

  NCT06314282· Forrás

• Fut, nem toboroz

  Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

  NCT02542293· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Gyermekkori daganatok2 toboroz
• Áttétes emlőrák1 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
• Máj- és epeúti rák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

  NCT06125314· Forrás

• Lezárult

  Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients

  NCT05603845· Forrás

• Lezárult

  A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

  NCT06039683· Forrás